LL-37

LL-37 is the only known human cathelicidin antimicrobial peptide — a 37-amino-acid alpha-helical peptide cleaved from the hCAP-18 precursor protein. It is a critical component of the innate immune system.

LL-37 is the body's built-in broad-spectrum antibiotic and immune coordinator. It punches holes in bacteria, neutralizes viruses, and tells the immune system what to do next — all from one peptide.

Disrupts microbial membranes directly via amphipathic alpha-helix insertion, killing bacteria, viruses, and fungi without specific receptor binding. It also modulates innate immunity by chemoattracting neutrophils, monocytes, and T-cells, and by influencing dendritic cell function. Low LL-37 expression has been associated with multiple chronic infection and biofilm-related research models.

• •Broad-spectrum antimicrobial activity
• •Biofilm disruption studies
• •Chronic Lyme and biotoxin research
• •Wound healing and skin barrier research
• •Immune modulation studies

Discussed extensively in chronic-infection, Lyme-research, and mold-illness communities. Conversations focus on biofilm penetration and broad antimicrobial coverage. Side-effect discussions note potential histamine release at higher doses.

“The body's own broad-spectrum antibiotic.”

Often stacked with Thymosin Alpha-1 for chronic-infection research, with KPV for inflammation, and with BPC-157 for tissue repair after immune challenge.

LL-37 is the only human cathelicidin, a 37-amino-acid antimicrobial and immunomodulatory peptide studied for broad antimicrobial activity, biofilm disruption, and innate immunity.